Genmab A/S ADS
GMABStock
$28.98+37.59%52W
Market Cap$111.07B
P/E17.61x
Div yield—
Beta0.56
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.86%
Price vs S&P 500 (4W)15.94%
VGM Score54.39
Market Capitalization$111.07B
P/E Ratio (Annual)17.61x
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.70
3.78
3.84
3.88
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GMABGenmab A/S ADS | C | C | B | $28.98 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Genmab is a Copenhagen-based biotechnology company developing antibody therapeutics for cancer treatment, leveraging proprietary platforms including DuoBody, HexaBody, and DuoHexaBody. The company has a portfolio of approved products including Darzalex (the standard of care for multiple myeloma), Tepezza, Kesimpta, and others developed through strategic partnerships with major pharmaceutical companies. Genmab maintains a pipeline of candidates targeting additional oncologic indications.